| Metric | Value (₹ Cr) | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue | 424.68 | 4.6% | 23.0% |
| Total Income | 432.84 | 4.3% | 22.9% |
| Expenditure | 363.19 | 4.2% | 14.8% |
| PBT | 69.76 | 22.1% | 93.5% |
| Net Profit | 50.96 | 21.1% | 74.3% |
| OPM | 25.46% | 4.33pp | 7.42pp |
| NPM | 11.77% | 1.63pp | 3.47pp |
| EPS | 2.46 | 69.2% | 56.8% |
Metropolis Healthcare Q4FY26: EBITDA up 71% YoY, PAT rises 75%
13 May 2026 · 13 May, 8:12 pm
Summary
Metropolis Healthcare Limited announced strong financial results for Q4FY26 and the full fiscal year 2026, driven by robust demand and operational efficiencies. For the fourth quarter, consolidated revenue from operations grew 23.0% year-over-year to ₹424.7 crore, while Profit After Tax (PAT) significantly increased by 74.5% to ₹51.0 crore. Full-year FY26 consolidated revenue rose 23.6% to ₹1,645.8 crore, with PAT up 31.4% to ₹191.2 crore. The company achieved a major business milestone by expanding its network beyond 5,000 centres across India and its Board approved a dividend of ₹1 per share. Ms. Ameera Shah, Chairperson, emphasized Metropolis's commitment to scientific excellence and advanced diagnostics, positioning it well in the evolving healthcare landscape.
Key Highlights
- 1
Metropolis Healthcare reported Q4FY26 consolidated revenue from operations of ₹424.7 crore, marking a 23.0% growth year-over-year.
- 2
Profit After Tax (PAT) for Q4FY26 surged by 74.5% year-over-year to ₹51.0 crore, reflecting improved profitability.
- 3
EBITDA for Q4FY26 increased significantly by 71.3% year-over-year to ₹108.0 crore, with a reported EBITDA margin of 25.4%.
- 4
For the full fiscal year 2026, consolidated revenue from operations reached ₹1,645.8 crore, an increase of 23.6% compared to FY25.
- 5
FY26 Profit After Tax grew by 31.4% to ₹191.2 crore, and EBITDA for the year was ₹400.8 crore, up 31.7% from FY25.
- 6
The company crossed the significant milestone of 5,000+ centres, enhancing its accessibility and market presence across India.
- 7
The Board of Directors approved a dividend of ₹1 per share.
Management Comments
Ms. Ameera Shah
The diagnostics industry in India is evolving towards more organised and science-led platforms, driven by increasing focus on trust, accuracy and clinical excellence. At Metropolis, our focus on scientific excellence, strong doctor relationships and advanced diagnostics positions us well in this evolving healthcare landscape. In Q4FY26, Metropolis delivered robust growth, with revenue increasing 23% YoY, while expanding our network beyond 5,000 centres across India. With healthcare increasingly moving towards preventive and personalised care, we remain committed to building a differentiated diagnostics platform driven by quality, innovation and customer trust.
Informational and educational content only. Not investment advice.